History

When Michael Zang-Gandor and Dr. Christine Gandor founded EUGENEX Biotechnologies GmbH in 1999, they utilized 10+ years of experience and skills in mammalian cell culture, molecular genetics, and gene expression. The EUGENEX team established the first expression system with a unique, animal component-free technology platform that satisfies all regulatory requirements.

EUGENEX has always worked independently from outside investors. This affords the company the flexibility to take on ambitious projects, pivot when necessary and follow their own convictions. Within two decades EUGENEX Biotechnologies has become a major provider of cell lines and processes for the biopharmaceutical industry.

EUGENEX – A Success Story

2021	-	Launch of a monoclonal antibody derived from a EUGENEX Cell Line/Process

2020	-	EUGENEX develops a novel therapeutic agent against Covid-19 (Coronavirus SARS-CoV-2)

2019	-	10 biosimilars derived from EUGENEX’s cell lines are on the market
	-	Launch of a monoclonal antibody derived from a EUGENEX Cell Line/Process

2018	-	20th anniversary of EUGENEX Biotechnologies
		Food and Drug Administration (FDA) approval of a biosimilar derived from a EUGENEX Cell Line/Process

2017	-	Launch of a monoclonal antibody derived from a EUGENEX Cell Line/Process

2016	-	Launch of a monoclonal antibody derived from a EUGENEX Cell Line/Process

2015	-	Launch of a monoclonal antibody derived from a EUGENEX Cell Line/Process

2014	-	Launch of a glycosylated cytokine derived from a EUGENEX Cell Line/Process

2013	-	Launch of a glycosylated cytokine derived from a EUGENEX Cell Line/Process

2008	-	First biosimilar derived from a EUGENEX Cell Line/Process reaches the non-regulated market

2007	-	First biosimilar derived from a EUGENEX Cell Line/Process reaches the European market

2006	-	Winner of an international innovation prize with the project: "Biological Coating for Implants"

2005	-	European Medicines Agency (EMA) approves a biosimilar derived from a EUGENEX Cell Line/Process

2004	-	First tech transfer of USP for biosimilar production
	-	Winner of an international innovation prize with the project: "Detection and Validation System of New Medically Effective Substances"

2003	-	Winner of an international innovation prize with the project "Development and Production System of High-Quality Recombinant Proteins"

2000	-	Relocation of EUGENEX Biotechnologies to larger premises in Taegerwilen, Lake of Constance, Switzerland

1999	-	Development of first commercial production cell line
	-	Establishment of EUGENEX platform for cell line development
	-	Establishment of EUGENEX Biotechnologies GmbH

1998	-	Establishment of EUGENEX Biotechnologies laboratories in Matzingen, Switzerland